2,2′-Dihydroxy-4,4′-dimethoxybenzophenone-5,5′-disulphonic acid sodium salt

We are 2,2′-Dihydroxy-4,4′-dimethoxybenzophenone-5,5′-disulphonic acid sodium salt CAS:76656-36-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 2,2'-Dihydroxy-4,4'-dimethoxybenzophenone-5,5'-disulphonic acid sodium salt
Other Name: Disodium 4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate;Disodium 2,2'-dihydroxy-4,4'-dimethoxy-5,5'-disulfobenzophenone
CAS No: 76656-36-5
MF: C15H12Na2O11S2
MW: 478.35900
Melting point: 350°C (dec.)
UN Number: UN1325
Transport hazard class: 4.1
Packing group: II
Appearance: Light yellow crystalline powder
Assay: ≥98%
Hazen: ≤6.0
K value(330nm): ≥16.0
Widely used in water-soluble cosmetics, water-soluble inks, paints, paints.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

2,2'-Dihydroxy-4,4'-dimethoxybenzophenone-5,5'-disulphonic acid sodium salt

Related News: The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds.126534-31-4 ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.32955-21-8 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.6-(Trifluoromethyl)nicotinic acid Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).

Related Products
Product Name
2-bromo-6-fluoro-4-methylpyridine View Details
3-Chloro-o-xylene View Details
3-Amino-3-azabicyclo[3.3.0]octane hydrochloride View Details
2-Bromo-1-(4-methoxyphenyl)ethanone manufacturer 3-(1-ethoxyethoxy)-4-phenylazetidin-2-one manufacturer 2-Chloro-4-iodo-3-methylpyridine manufacturer 2-(Trifluoromethoxy)benzonitrile manufacturer ditert-butyl-[[2-(ditert-butylphosphanylmethyl)phenyl]methyl]phosphane manufacturer